Treatment of stage III non-small cell lung cancer in the era of immunotherapy: pathological complete response to neoadjuvant pembrolizumab and chemotherapy

Non-small cell lung cancer (NSCLC) accounts for about 85% of all lung cancers. The expected 5-year survival of stage III NSCLC ranges from 13% to 36% for stage III. Due to the heterogeneity and poor efficacy of stage III patients, there is great controversy on how to optimize the therapy strategy. I...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Transl Lung Cancer Res
Main Authors: Yang, Zhang-Ru, Liu, Mi-Na, Yu, Jia-Hua, Yang, Yun-Hai, Chen, Tian-Xiang, Han, Yu-Chen, Zhu, Lei, Zhao, Ji-Kai, Fu, Xiao-Long, Cai, Xu-Wei
Format: Artigo
Jezik:Inglês
Izdano: AME Publishing Company 2020
Teme:
Review Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7653116/
https://ncbi.nlm.nih.gov/pubmed/33209626
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/tlcr-20-896
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki